2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States

In the 2015-2016 season, quadrivalent live attenuated influenza vaccine (LAIV) and both trivalent and quadrivalent inactivated influenza vaccine (IIV) were available in the United States. This study, conducted according to a test-negative case-control design, enrolled children aged 2-17 years presen...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2018-03, Vol.66 (5), p.665-672
Main Authors: Poehling, Katherine A, Caspard, Herve, Peters, Timothy R, Belongia, Edward A, Congeni, Blaise, Gaglani, Manjusha, Griffin, Marie R, Irving, Stephanie A, Kavathekar, Poornima K, McLean, Huong Q, Naleway, Allison L, Ryan, Kathleen, Talbot, H Keipp, Ambrose, Christopher S
Format: Article
Language:English
Subjects:
Adolescent
and Commentaries
Case-Control Studies
Child
Child, Preschool
Children
Children & youth
Confidence intervals
Female
Fever
Humans
Influenza
Influenza A
Influenza A Virus, H1N1 Subtype
Influenza A Virus, H3N2 Subtype
Influenza B
Influenza B virus
Influenza Vaccines - immunology
Influenza Vaccines - therapeutic use
Influenza, Human - epidemiology
Influenza, Human - prevention & control
Logistic Models
Male
Nose - virology
Polymerase chain reaction
Regression analysis
Regression models
Seasons
Statistical analysis
United States - epidemiology
Vaccination - statistics & numerical data
Vaccine efficacy
Vaccine Potency
Vaccines
Vaccines, Attenuated - immunology
Vaccines, Attenuated - therapeutic use
Vaccines, Inactivated - immunology
Vaccines, Inactivated - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the 2015-2016 season, quadrivalent live attenuated influenza vaccine (LAIV) and both trivalent and quadrivalent inactivated influenza vaccine (IIV) were available in the United States. This study, conducted according to a test-negative case-control design, enrolled children aged 2-17 years presenting to outpatient settings with fever and respiratory symptoms for
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/cix869